These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30587545)

  • 1. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
    Wasserman I; Lee LH; Ogino S; Marco MR; Wu C; Chen X; Datta J; Sadot E; Szeglin B; Guillem JG; Paty PB; Weiser MR; Nash GM; Saltz L; Barlas A; Manova-Todorova K; Uppada SPB; Elghouayel AE; Ntiamoah P; Glickman JN; Hamada T; Kosumi K; Inamura K; Chan AT; Nishihara R; Cercek A; Ganesh K; Kemeny NE; Dhawan P; Yaeger R; Sawyers CL; Garcia-Aguilar J; Giannakis M; Shia J; Smith JJ
    Clin Cancer Res; 2019 Mar; 25(6):1948-1956. PubMed ID: 30587545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
    Zhang B; Zhang B; Chen X; Bae S; Singh K; Washington MK; Datta PK
    Br J Cancer; 2014 Feb; 110(4):946-57. PubMed ID: 24384683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
    Dost Gunay FS; Kırmızı BA; Ensari A; İcli F; Akbulut H
    Clin Colorectal Cancer; 2019 Jun; 18(2):e244-e250. PubMed ID: 30670344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
    Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Hase K; Yamamoto J; Ueno H
    Dis Colon Rectum; 2019 Nov; 62(11):1316-1325. PubMed ID: 31567925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
    Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
    Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
    J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
    J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
    Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
    Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value.
    Shi DD; Yang CG; Han S; Wang SY; Xiong B
    Oncol Rep; 2020 Aug; 44(2):757-767. PubMed ID: 32627039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
    Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
    Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers.
    Yoo SY; Park HE; Kim JH; Wen X; Jeong S; Cho NY; Gwon HG; Kim K; Lee HS; Jeong SY; Park KJ; Han SW; Kim TY; Bae JM; Kang GH
    Clin Cancer Res; 2020 Feb; 26(4):870-881. PubMed ID: 31757879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.